BR112022023168A2 - Vhh contra a proteína spike de sars-cov-2 e métodos para a detecção de sars-cov-2 e para a neutralização de sars-cov-2 - Google Patents

Vhh contra a proteína spike de sars-cov-2 e métodos para a detecção de sars-cov-2 e para a neutralização de sars-cov-2

Info

Publication number
BR112022023168A2
BR112022023168A2 BR112022023168A BR112022023168A BR112022023168A2 BR 112022023168 A2 BR112022023168 A2 BR 112022023168A2 BR 112022023168 A BR112022023168 A BR 112022023168A BR 112022023168 A BR112022023168 A BR 112022023168A BR 112022023168 A2 BR112022023168 A2 BR 112022023168A2
Authority
BR
Brazil
Prior art keywords
cov
sars
neutralization
detection
methods
Prior art date
Application number
BR112022023168A
Other languages
English (en)
Inventor
Rojas Alejandro
Valenzuela Guillermo
Jara Ronald
Himelreichs Johanna
Salinas Constanza
Pinto Teresa
López Natalia
Cheuquemilla Yorka
Cuevas Alexei
Miranda Zaray
Uberti Benjamín
Muller Ananda
Original Assignee
Univ Austral De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Austral De Chile filed Critical Univ Austral De Chile
Publication of BR112022023168A2 publication Critical patent/BR112022023168A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Abstract

VHH CONTRA A PROTEÍNA SPIKE DE SARS-COV-2 E MÉTODOS PARA A DETECÇÃO DE SARS-COV-2 E PARA A NEUTRALIZAÇÃO DE SARS-COV2. A invenção fornece um conjunto de novos anticorpos VHH de domínio único contra o SARS-COV-2 (SEQ ID n.º 1-6) e a sua utilização para detectar e neutralizar o vírus de tipo selvagem.
BR112022023168A 2020-05-15 2021-05-14 Vhh contra a proteína spike de sars-cov-2 e métodos para a detecção de sars-cov-2 e para a neutralização de sars-cov-2 BR112022023168A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063025534P 2020-05-15 2020-05-15
PCT/IB2021/054171 WO2021229540A2 (en) 2020-05-15 2021-05-14 Single domain vhh antibodies against sars-cov-2 virus

Publications (1)

Publication Number Publication Date
BR112022023168A2 true BR112022023168A2 (pt) 2023-02-07

Family

ID=78525891

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023168A BR112022023168A2 (pt) 2020-05-15 2021-05-14 Vhh contra a proteína spike de sars-cov-2 e métodos para a detecção de sars-cov-2 e para a neutralização de sars-cov-2

Country Status (9)

Country Link
US (2) US20230324403A1 (pt)
EP (2) EP4149626A2 (pt)
KR (1) KR20230065931A (pt)
CN (2) CN115917061A (pt)
AR (1) AR122104A1 (pt)
BR (1) BR112022023168A2 (pt)
CA (1) CA3178663A1 (pt)
CL (2) CL2022003173A1 (pt)
WO (3) WO2021229540A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115043936B (zh) * 2022-03-31 2023-06-27 深圳市人民医院 靶向新冠病毒的纳米抗体及其制备方法和应用
CN114478758B (zh) * 2022-04-01 2022-06-21 深圳市人民医院 靶向SARS-CoV-2的纳米抗体及制备方法和应用
CN116375852B (zh) * 2023-03-10 2024-02-02 华南农业大学 重组荧光纳米抗体及其在制备狂犬病病毒检测试剂中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2267032A3 (en) * 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
US20130332133A1 (en) * 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
US20110076752A1 (en) * 2007-02-09 2011-03-31 Medimmune, Llc Antibody library display by yeast cell plasma membrane
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US20110214205A1 (en) * 2010-02-26 2011-09-01 Monsanto Technology Llc. Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits

Also Published As

Publication number Publication date
EP4151784A1 (en) 2023-03-22
CL2022003173A1 (es) 2023-07-07
CN115917061A (zh) 2023-04-04
AR122104A1 (es) 2022-08-10
CA3178663A1 (en) 2021-11-18
US20230324403A1 (en) 2023-10-12
KR20230065931A (ko) 2023-05-12
WO2021229540A3 (en) 2021-12-23
EP4149626A2 (en) 2023-03-22
CN115867350A (zh) 2023-03-28
WO2021229540A2 (en) 2021-11-18
WO2021226728A1 (es) 2021-11-18
WO2021226729A1 (es) 2021-11-18
US20240067705A1 (en) 2024-02-29
CL2022003165A1 (es) 2023-03-24

Similar Documents

Publication Publication Date Title
BR112022023168A2 (pt) Vhh contra a proteína spike de sars-cov-2 e métodos para a detecção de sars-cov-2 e para a neutralização de sars-cov-2
CY1122593T1 (el) Αντισωματα εναντι-cd40 και χρησεις αυτων
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
CY1124664T1 (el) Υποδοχεις τ λεμφοκυτταρων
CY1125008T1 (el) Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων
CY1123068T1 (el) Εξουδετερωτικα αnτισωματα εναντι gp120 και χρηση αυτων
BR112022017986A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112018070260A2 (pt) receptores quiméricos e métodos de uso dos mesmos
CL2023000895A1 (es) Receptores quiméricos de dll3 y métodos para su uso
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
BR112019005964A2 (pt) proteínas de fusão imunomoduladoras
Bar-On et al. Neuraminidase-mediated, NKp46-dependent immune-evasion mechanism of influenza viruses
CY1120055T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
BR112016016737A2 (pt) Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
BR112022004534A2 (pt) Anticorpos de domínio único direcionados contra lilrb2
EA202191931A1 (ru) Способ характеризации видимых и/или невидимых частиц в биологических препаратах
Muramatsu et al. Heterosubtypic antiviral activity of hemagglutinin-specific antibodies induced by intranasal immunization with inactivated influenza viruses in mice
EA202190382A1 (ru) Фармацевтические составы на основе маскированных антител
BR112021012792A2 (pt) Anticorpos monoclonais específicos para o antígeno pb2 do vírus da influenza humana (flu), sequências nucleotídeas, método e kit de diagnóstico de infecção produzida por flu
MX2021002250A (es) Dominio de nucleasa novedoso y uso del mismo.
GB2541596A (en) Method and composition for determining specific antibody responses to species of filovirus
Molesti et al. Discordant correlation between serological assays observed when measuring heterosubtypic responses against avian influenza H5 and H7 viruses in unexposed individuals
EA202092963A1 (ru) Новый белок с противовоспалительными свойствами
AR102966A1 (es) ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO M DEL VIRUS METAPNEUMOVIRUS HUMANO (hMPV), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR hMPV